Related Experiment Video

Updated: Jun 16, 2026

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time
06:01

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time

Published on: July 26, 2024

[PPARgamma agonists for the diseases of gastrointestinal tract and liver]

Tadahito Shimada1, Hideyuki Hiraishi

  • 1Department of Gastroenterology, Dokkyo Medical University.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|February 18, 2010
PubMed

Insights

Thiazolidinedione (TZD) drugs targeting PPARgamma show promise for colon cancer prevention and treating inflammatory bowel diseases (IBD). Further clinical studies are needed to confirm their efficacy in gastroenterology.

Area of Science:

  • Molecular biology and gastroenterology research.
  • Focus on nuclear receptor superfamily and colonic epithelial cells.

Context:

  • High expression of PPARgamma in colonic epithelial cells suggests a key physiological role.
  • In vitro and animal studies demonstrate anti-cancer and anti-inflammatory effects of TZD PPARgamma agonists.

Purpose:

  • To investigate the potential of thiazolidinedione (TZD) drugs as treatments for colorectal cancer and inflammatory bowel diseases (IBD).
  • To evaluate the efficacy of PPARgamma agonists in gastrointestinal conditions.

Summary:

  • PPARgamma agonists, specifically thiazolidinediones (TZDs), exhibit significant anti-cancer and anti-inflammatory properties in the colon.
  • Preclinical data suggest TZD efficacy in colorectal cancer chemoprevention and mild to moderate IBD treatment.

Impact:

  • TZDs may offer a novel therapeutic strategy for colorectal cancer and inflammatory bowel diseases.
  • Limited clinical evidence necessitates further investigation to establish TZD utility in gastroenterology practice.

More Related Videos

Gastrointestinal Motility Monitor (GIMM)08:15

Gastrointestinal Motility Monitor (GIMM)

Published on: December 1, 2010

Related Concept Videos

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...